Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Sab Biotherapeutics Inc (SABS)

Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Thu Mar 19, 3:01PM CDT

MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Mar 17, 9:46PM CDT

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Mar 17, 3:01PM CDT

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes GlobeNewswire - Tue Mar 10, 6:31AM CDT

Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10,...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights GlobeNewswire - Mon Mar 9, 4:16PM CDT

Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Mar 2, 8:00AM CST

MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 4, 8:00AM CST

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director GlobeNewswire - Wed Jan 7, 7:00AM CST

David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ),...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Jan 6, 7:00AM CST

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes...

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D GlobeNewswire - Thu Dec 18, 2025

Enrollment in the SAFEGUARD trial is ongoing at multiple centers globally Company on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc....

SABSW : 0.0280 (+7.28%)
SABS : 3.88 (+0.26%)

Barchart Exclusives

The Next Big AI Winner Might Not Be a Tech Company Barchart - Sat Apr 4, 10:30AM CDT
Lilly’s AI push shows how non-tech firms can dominate the next wave. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.